share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Exchange Traded Concepts LLC Sells 46,238 Shares of Hologic, Inc. (NASDAQ:HOLX)

Defense World ·  10/02 17:41

Exchange Traded Concepts LLC lowered its holdings in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 72.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,592 shares of the medical equipment provider's stock after selling 46,238 shares during the quarter. Exchange Traded Concepts LLC's holdings in Hologic were worth $1,219,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. New England Research & Management Inc. acquired a new position in Hologic in the second quarter valued at about $381,000. Frontier Capital Management Co. LLC boosted its position in Hologic by 31.0% in the second quarter. Frontier Capital Management Co. LLC now owns 688,472 shares of the medical equipment provider's stock valued at $47,711,000 after buying an additional 162,843 shares in the last quarter. Denali Advisors LLC boosted its position in Hologic by 225.0% in the second quarter. Denali Advisors LLC now owns 7,800 shares of the medical equipment provider's stock valued at $541,000 after buying an additional 5,400 shares in the last quarter. Heritage Financial Services LLC acquired a new position in Hologic in the second quarter valued at about $27,000. Finally, Brinker Capital Investments LLC boosted its position in Hologic by 271.9% in the second quarter. Brinker Capital Investments LLC now owns 78,547 shares of the medical equipment provider's stock valued at $5,443,000 after buying an additional 57,426 shares in the last quarter. 85.70% of the stock is currently owned by institutional investors and hedge funds.

Get Hologic alerts:

Hologic Trading Down 0.7 %

Shares of NASDAQ HOLX opened at $64.52 on Friday. The company's 50 day simple moving average is $68.85 and its 200 day simple moving average is $72.05. Hologic, Inc. has a fifty-two week low of $61.57 and a fifty-two week high of $80.49. The firm has a market capitalization of $16.11 billion, a P/E ratio of 10.88, a P/E/G ratio of 0.74 and a beta of 1.05. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX – Get Rating) last announced its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.26. Hologic had a net margin of 28.93% and a return on equity of 37.48%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $896.71 million. During the same period in the prior year, the business posted $1.33 earnings per share. Hologic's revenue was down 14.2% compared to the same quarter last year. On average, analysts predict that Hologic, Inc. will post 5.82 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of a number of recent analyst reports. Morgan Stanley reduced their price target on shares of Hologic from $72.00 to $70.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 28th. BTIG Research lowered shares of Hologic from a "buy" rating to a "neutral" rating in a research report on Monday, July 18th. Bank of America lowered shares of Hologic from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $81.00 to $75.00 in a research report on Wednesday, July 20th. Finally, UBS Group initiated coverage on shares of Hologic in a research report on Wednesday, July 20th. They set a "neutral" rating and a $73.00 target price on the stock. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $76.71.

About Hologic

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Featured Stories

  • Get a free copy of the StockNews.com research report on Hologic (HOLX)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Let Paychex Stock Work Hard For You
  • How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Get Rating).

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.